COSCIENS Biopharma Inc.
CSCI · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $2,749 | $1,495 | $3,322 | $1,871 |
| % Growth | 83.8% | -55% | 77.6% | – |
| Cost of Goods Sold | $1,775 | $1,054 | $1,273 | $914 |
| Gross Profit | $974 | $442 | $2,049 | $837 |
| % Margin | 35.4% | 29.5% | 61.7% | 44.7% |
| R&D Expenses | $690 | $1,131 | $2,913 | $2,799 |
| G&A Expenses | $0 | $0 | $0 | $2,992 |
| SG&A Expenses | $2,637 | $2,917 | $2,746 | $2,992 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $2,798 | $1,459 |
| Operating Expenses | $3,327 | $4,048 | $8,457 | $7,250 |
| Operating Income | -$2,353 | -$3,606 | -$6,408 | -$6,293 |
| % Margin | -85.6% | -241.1% | -192.9% | -336.3% |
| Other Income/Exp. Net | -$347 | -$38 | $759 | $426 |
| Pre-Tax Income | -$2,700 | -$3,644 | -$5,649 | -$5,867 |
| Tax Expense | $1 | $0 | $1,082 | -$112 |
| Net Income | -$2,701 | -$3,644 | -$6,731 | -$5,755 |
| % Margin | -98.3% | -243.7% | -202.6% | -307.6% |
| EPS | -0.85 | -1.16 | -2.35 | -1.85 |
| % Growth | 26.7% | 50.6% | -27% | – |
| EPS Diluted | -0.85 | -1.16 | -2.35 | -1.85 |
| Weighted Avg Shares Out | 3,175 | 3,145 | 2,863 | 3,107 |
| Weighted Avg Shares Out Dil | 3,175 | 3,145 | 2,863 | 3,107 |
| Supplemental Information | – | – | – | – |
| Interest Income | $83 | $106 | $429 | $0 |
| Interest Expense | $23 | $70 | $22 | $22 |
| Depreciation & Amortization | $287 | $324 | $392 | $479 |
| EBITDA | -$2,390 | -$3,250 | -$5,234 | -$5,366 |
| % Margin | -86.9% | -217.3% | -157.6% | -286.8% |